Scientists Discover "Mitch" Protein That Controls Fat Burning, Opening New Path for Obesity Treatments

In a discovery that could fundamentally change how obesity is treated, scientists at the Weizmann Institute of Science in Israel have identified a protein called MTCH2 — nicknamed "Mitch" — that acts as a master regulator of fat burning in human cells. When the protein is switched off, human cells dramatically increase their fat-burning rate and stop forming new fat cells altogether.

The Serendipitous Discovery of Mitch

Professor Atan Gross and his team at the Weizmann Institute originally stumbled upon Mitch while studying mouse genes several years ago. When they turned off the Mitch gene in mice, something remarkable happened: the animals became resistant to obesity, and their athletic endurance soared due to a significant boost in metabolic activity. Now, in a study published in The EMBO Journal, Gross's team has shown that the same mechanism works in human cells.

"We discovered that deleting Mitch led to a major drop in fats in membranes," Gross explained. The cells without Mitch began burning fat as their primary fuel source instead of carbohydrates and proteins, fundamentally altering their energy metabolism.

How Mitch Controls Fat Metabolism

MTCH2 is a protein that lives on the surface of mitochondria — the energy-producing factories within cells. The researchers found that Mitch is responsible for mitochondrial fusion and fat cell differentiation, the process by which progenitor cells accumulate fat and turn into mature fat cells. When Mitch is silenced, the supply of fatty substances needed to build cell membranes is redirected toward energy production instead.

"Reducing the ability to synthesize membranes prevents the cells from growing, developing and reaching the point where differentiation is possible," Gross said. "Fat accumulation requires a large amount of available energy, but in cells without Mitch, there is a shortage of energy." As a result, new fat cell formation is reduced, and existing fat is burned more aggressively.

The study also found that women with obesity have elevated levels of Mitch, suggesting the protein plays a direct role in human obesity. The research team is now working with Yeda Research and Development Company, Weizmann's technology transfer arm, to develop compounds that could block Mitch's activity as a potential obesity treatment.

Why This Matters Beyond Ozempic

Current blockbuster obesity drugs like Ozempic, Wegovy, and Mounjaro work by suppressing appetite through GLP-1 hormone pathways. While effective, they require ongoing injections, can cause significant side effects, and do not address the underlying metabolic machinery that determines how the body processes energy. A therapy targeting Mitch would work at the cellular level, potentially offering a fundamentally different approach to weight management.

The Mitch discovery targets the root cause of fat accumulation rather than appetite. If a safe drug can be developed to block Mitch in humans, it could offer an alternative for patients who cannot tolerate GLP-1 drugs or who regain weight after stopping them. The obesity treatment market, currently valued at over $100 billion annually, is actively seeking therapies with complementary mechanisms of action.

This discovery builds on a growing body of research into cellular metabolism. Recent studies have also uncovered the structure of UCP1, a protein that allows brown fat to burn calories as heat, and found that a protein called HSL controls fat cell health from inside the nucleus. Together, these advances suggest that the next generation of obesity treatments will target metabolism at multiple points.

Obesity in India: A Growing Crisis

Obesity is a rapidly escalating health challenge in India. According to the National Family Health Survey, nearly one in four Indians is now overweight or obese, and the prevalence has more than doubled in the last decade. Urban India, in particular, has seen sharp increases driven by changing diets and sedentary lifestyles. Obesity is a major risk factor for diabetes, heart disease, and certain cancers — conditions that already place enormous strain on India's healthcare system.

A therapy based on the Mitch discovery could be particularly impactful for India, where access to expensive injectable GLP-1 drugs remains limited. A pill-based treatment targeting cellular metabolism would be more scalable and affordable, potentially reaching millions of patients who currently have no effective medical option for weight management. For perspective on the broader landscape of cellular-level therapeutic discoveries and protein-targeting drug research, see our related science coverage.

Frequently Asked Questions

What is the Mitch protein?

Mitch is the nickname for MTCH2, a protein found on the surface of mitochondria that regulates how cells process energy. When active, it promotes fat storage; when silenced, it causes cells to burn fat for energy instead.

Is there a drug for Mitch yet?

Not yet. The research is at the preclinical stage. The Weizmann Institute's technology transfer arm, Yeda, is working to develop compounds that can block Mitch, but human clinical trials are likely years away.

How is this different from Ozempic?

Ozempic and similar GLP-1 drugs suppress appetite by mimicking a gut hormone. A Mitch-targeting therapy would work at the cellular level, directly reprogramming how fat cells form and metabolise energy — potentially offering a complementary or alternative approach.

Could this help with obesity in India?

Potentially yes. A pill-based treatment targeting metabolism could be more scalable and affordable than injectable GLP-1 drugs, making it accessible to a larger population. However, clinical development and regulatory approval would take several years.

Sources

Sources: SciTechDaily, IFLScience, The EMBO Journal, Weizmann Institute of Science